Bone Health Technologies

Bone Health Technologies is a producer of next-gen technology to treat and prevent Osteoporosis. The company’s core product, the OsteoBoost, is a vibrating belt that applies stimulation to the hips and spine to reduce bone loss activity. It is based on NASA research which proved that bone health in astronauts can be improved by vibration-induced medical stimulation of bones. In December 2020, the OsteoBoost was granted FDA Breakthrough Device status.

As of May 2021, the device is being tested at the National Institute for Health (NIH). The company’s preliminary studies have shown that a 30-minute treatment with OsteoBoost reduced bone loss across all participants. Due to the positive results, the NIH had funded a broader USD 2 million study to be completed in early 2022. In January 2024, the FDA approved the product for treating low bone density for postmenopausal women.

In July 2024, the company acquired Wellen, a Brooklyn-based company focused on personalized exercise programs for osteoporosis, for an undisclosed sum. Wellen specializes in creating personalized, science-backed exercise programs for women over 50 to address osteoporosis. The company aimed to strengthen bones and reduce the risk of falls and fractures through customized exercise routines developed by physical therapists. Bone Health Technologies planned to integrate Wellen's expertise with its FDA-cleared Osteoboost vibration therapy belt. This acquisition was expected to create a comprehensive, multi-modal bone health solution, offering patients targeted vibration therapy and personalized exercise programs to improve outcomes for those with low bone density.

In November 2024, the company launched Osteoboost, an FDA-cleared prescription wearable device for postmenopausal women with osteopenia. Osteoboost is a waist-worn device that delivers targeted hip and spine vibration therapy. The device uses a patented combination of dynamically calibrated frequency and amplitude, can be used during daily activities like walking or household chores, and features auto-calibrated mechanical vibrations within the therapeutic frequency range. The company noted that clinical trials conducted at the University of Nebraska Medical Center showed that Osteoboost reduced the loss of spinal bone density by 85% and bone strength by 83%.